Skip to main content

Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.

Publication ,  Journal Article
Vrionis, FD; Wikstrand, CJ; Fredman, P; Månsson, JE; Svennerholm, L; Bigner, DD
Published in: Cancer Res
December 1, 1989

In order to investigate GM2 expression in gliomas, the GM2-positive human glioma cell line (HGL) D-54 MG, which contains 0.6 nmol GM2/mg protein, representing 77% of the total monosialoganglioside fraction, was used as an immunogen for the production of anti-GM2 monoclonal antibodies. For ganglioside designations, see IUPAC-IUB (Eur. J. Biochem., 79: 11-21, 1977) and Svennerholm (J. Neurochem., 10: 613-623, 1963). Five IgM monoclonal antibodies (DMAb-1 through DMAb-5) specifically recognizing the GalNAc beta1-4(NeuAc alpha 2-3)Gal-terminal epitope common to GM2 and GalNAC-GD1a are reported. The antibodies did not react with GM1, GM3, GD2, GD3, GD1a, GD1b, and GQ1b. Purified anti-GM2 MAbs were used to define the expression of the "GM2" terminal epitope by cultured human malignant and normal cells by radioimmunoassay and membrane immunofluorescence. Among neuroectodermal tissue-derived cell lines, DMAb-3, at an optimal concentration of 5 micrograms/ml, showed high reactivity (radioimmunoassay binding ratios greater than 20) with 9 of 19 HGLs, 3 of 5 medulloblastoma, 4 of 5 neuroblastoma, and 1 of 3 melanoma lines. Moderate reactivity (binding ratio, 10-20) was exhibited by 3 HGL, 2 medulloblastoma, and 1 neuroblastoma lines and low reactivity (binding ratio, 3-10) by 5 HGL lines; no reactivity was detected with 2 HGL and 2 melanoma lines. Densitometric evaluation of monosialoganglioside extracts from human glioma and medulloblastoma cell lines in conjunction with immunostaining on thin-layer chromatograms showed that GM2 represents the major monosialoganglioside in 8 of 10 HGL and in 3 of 4 Med lines. In these lines the amount of GM2 ranged from less than 0.1 to 0.6 nmol/mg protein. These results indicate that GM2 represents a proportionally increased ganglioside of most glioma, medulloblastoma, and neuroblastoma cells in vitro.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

December 1, 1989

Volume

49

Issue

23

Start / End Page

6645 / 6651

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Melanoma
  • Medulloblastoma
  • Humans
  • Glioma
  • Gangliosides
  • G(M2) Ganglioside
  • Epitopes
  • Dose-Response Relationship, Immunologic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vrionis, F. D., Wikstrand, C. J., Fredman, P., Månsson, J. E., Svennerholm, L., & Bigner, D. D. (1989). Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. Cancer Res, 49(23), 6645–6651.
Vrionis, F. D., C. J. Wikstrand, P. Fredman, J. E. Månsson, L. Svennerholm, and D. D. Bigner. “Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.Cancer Res 49, no. 23 (December 1, 1989): 6645–51.
Vrionis FD, Wikstrand CJ, Fredman P, Månsson JE, Svennerholm L, Bigner DD. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. Cancer Res. 1989 Dec 1;49(23):6645–51.
Vrionis, F. D., et al. “Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.Cancer Res, vol. 49, no. 23, Dec. 1989, pp. 6645–51.
Vrionis FD, Wikstrand CJ, Fredman P, Månsson JE, Svennerholm L, Bigner DD. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. Cancer Res. 1989 Dec 1;49(23):6645–6651.

Published In

Cancer Res

ISSN

0008-5472

Publication Date

December 1, 1989

Volume

49

Issue

23

Start / End Page

6645 / 6651

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Melanoma
  • Medulloblastoma
  • Humans
  • Glioma
  • Gangliosides
  • G(M2) Ganglioside
  • Epitopes
  • Dose-Response Relationship, Immunologic